Platelet glycoprotein IIb/IIIa inhibitors remain relevant in percutaneous coronary interventions for ACS patients with high risk of coronary thrombosis, massive thrombus, or no-reflow phenomenon.
What is the role of platelet glycoprotein IIb/IIIa inhibitors in the current treatment of acute coronary syndrome?
Despite decreased overall prescription rates, GP IIb/IIIa inhibitors remain a relevant therapeutic option in specific high-risk ACS scenarios during PCI.
Current management of patients with acute coronary syndrome (ACS) includes a dual antiplatelet therapy with acetylsalicylic acid and a platelet P2Y12 receptor inhibitor. For patients without a high risk of bleeding, prasugrel and ticagrelor are preferred, since their effect is more pronounced, less dependent on metabolism of a specific patient, and occurs faster that the effect of clopidogrel. The prescription rate of platelet glycoprotein IIb/IIIa (GP IIb / IIIa) receptor inhibitors has considerably decreased. However, these drugs remain relevant in percutaneous coronary interventions in patients with a high risk of coronary thrombosis or a massive coronary thrombus, in thrombotic complications of the procedure, and in the "no-reflow" phenomenon. The intravenous route of GP IIb / IIIa inhibitor administration provides their effectiveness in patients with difficulties of drug intake or with impaired absorption of oral medications. This review presents clinical and pharmacological characteristics of various GP IIb / IIIa inhibitors and data of randomized clinical studies and registries of recent years that evaluated results of their use in patients with ACS.
Сухинина et al. (Sat,) conducted a review in Acute coronary syndrome. Platelet glycoprotein IIb/IIIa inhibitors was evaluated. Platelet glycoprotein IIb/IIIa inhibitors remain relevant in percutaneous coronary interventions for ACS patients with high risk of coronary thrombosis, massive thrombus, or no-reflow phenomenon.